Bladder cancer patients who received the chemotherapy drug gemcitabine had significantly lower recurrence of their cancer, a clinical trial has revealed.
When an FDA advisory committee approved the first cannabidiol medicine for prescription use in epilepsy, it based its decision on recommendations of a UT Health San Antonio researcher.
Exposing the gut to chlamydia protects against subsequent infection in the genital tract and other tissues, researchers have discovered.
Personalized medicine is expected to be the new normal in medicine in the future. A new master’s degree in personalized molecular medicine will train students in these novel approaches.
A compound found in plants may serve as a preventive agent and treatment for oral cancer.
Nearly 4 in 5 Latino youth suffer at least one traumatic childhood experience such as poverty or abuse, a new study shows.
Scientists at UT Health San Antonio and UTHealth in Houston were awarded millions in grants to expand studies of a therapeutic antibody to stem the spread of breast cancer to the bone.
This year, 203 students from the Long School of Medicine were matched to 85 residency programs across the nation. They were also part of something special, as 2018 marks the 50th anniversary of the school.
UT Health San Antonio has entered into a landmark licensing deal to develop new treatments for breast cancer and spinal cord injuries.
A new era of aging research began when UT Health San Antonio broke ground on a new and expanded Sam & Ann Barshop Institute for Longevity & Aging Studies.